## Aaron M Bender

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7387511/aaron-m-bender-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 24                | 302                | 10                 | 17              |
|-------------------|--------------------|--------------------|-----------------|
| papers            | citations          | h-index            | g-index         |
| 24<br>ext. papers | 359 ext. citations | <b>5.1</b> avg, IF | 3.36<br>L-index |

| #  | Paper  | IF                | Citations |
|----|--|-------------------|-----------|
| 24 | Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M muscarinic acetylcholine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2021</b> , 56, 12847                  | 79 <sup>2.9</sup> |           |
| 23 | Discovery of the First Selective M Muscarinic Acetylcholine Receptor Antagonists with Antiparkinsonian and Antidystonic Efficacy. <i>ACS Pharmacology and Translational Science</i> , <b>2021</b> , 4, 1306-                                 | -1321             | 5         |
| 22 | Discovery of VU6028418: A Highly Selective and Orally Bioavailable M Muscarinic Acetylcholine Receptor Antagonist. <i>ACS Medicinal Chemistry Letters</i> , <b>2021</b> , 12, 1342-1349  | 4.3               | 2         |
| 21 | Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2021</b> , 47, 128193                           | 2.9               | 0         |
| 20 | Synthesis of Substituted 6,7-Dihydro-5-pyrrolo[2,3-]pyridazines/pyrazines via Catalyst-Free Tandem Hydroamination-Aromatic Substitution. <i>Journal of Organic Chemistry</i> , <b>2020</b> , 85, 6123-6130                                   | 4.2               | 4         |
| 19 | DARK Classics in Chemical Neuroscience: Carfentanil. ACS Chemical Neuroscience, 2020,  | 5.7               | 7         |
| 18 | Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 4193-4203                                  | 8.3               | 5         |
| 17 | Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M Positive Allosteric Modulators. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1035-1042   | 5.7               | 5         |
| 16 | Biased M receptor-positive allosteric modulators reveal role of phospholipase D in M-dependent rodent cortical plasticity. <i>Science Signaling</i> , <b>2019</b> , 12,  | 8.8               | 7         |
| 15 | The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 342-346  | 2.9               | 6         |
| 14 | The Muscarinic Acetylcholine Receptor M: Therapeutic Implications and Allosteric Modulation. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1025-1034  | 5.7               | 12        |
| 13 | Discovery and Optimization of Potent and CNS Penetrant M-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 1572-1581          | 5.7               | 7         |
| 12 | Structure-Activity Relationships of Pan-GICoupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 1818-1828  | 5.7               | 5         |
| 11 | Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. <i>Molecular Pharmacology</i> , <b>2018</b> , 94, 926-937   | 4.3               | 24        |
| 10 | Classics in Chemical Neuroscience: Xanomeline. ACS Chemical Neuroscience, 2017, 8, 435-443   | 5.7               | 26        |
| 9  | Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 2479-2483                                | 2.9               | 2         |
| 8  | Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 3576-3581 | 2.9               | 7         |

## LIST OF PUBLICATIONS

| 7 | Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. <i>Organic Letters</i> , <b>2017</b> , 19, 5693-5696  | 6.2               | 22 |
|---|--|-------------------|----|
| 6 | Classics in Chemical Neuroscience: Memantine. ACS Chemical Neuroscience, 2017, 8, 1823-1829  | 5.7               | 38 |
| 5 | Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy Expioid Receptor (MOR)/Expioid Receptor (DOR) Ligands. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 4985-98  | 8.3               | 30 |
| 4 | Rapid Synthesis of Boc-2464dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics. <i>ACS Medicinal Chemistry Letters</i> , <b>2015</b> , 6, 1199-203   | 4.3               | 13 |
| 3 | Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy lipioid receptor/lipioid receptor ligands. ACS Chemical Neuroscience, 2015, 6, 1428-35 | 5.7               | 22 |
| 2 | Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity lbpioid receptor (MOR) agonist/lbpioid receptor (DOR) antagonist ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2014</b> , 24, 548-51        | 2.9               | 12 |
| 1 | Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy lapioid receptor (MOR) agonist/lapioid receptor (DOR) antagonist ligands. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 2139                                     | 9 <sup>8</sup> 43 | 41 |